We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
-19.99%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$887M
AUM Growth
+$16.2M
Cap. Flow
+$129M
Cap. Flow %
14.54%
Top 10 Hldgs %
50.79%
Holding
136
New
23
Increased
31
Reduced
31
Closed
36

Top Buys

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$34.3M
2
AZN icon
AstraZeneca
AZN
+$20.1M
3
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$14.8M
4
VTRS icon
Viatris
VTRS
+$11.4M
5
TEVA icon
Teva Pharmaceuticals
TEVA
+$10.3M

Top Sells

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$44.9M
2
MRK icon
Merck
MRK
+$22.8M
3
GSK icon
GSK
GSK
+$21.9M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$8.53M
5
V icon
Visa
V
+$6.06M

Sector Composition

Rank Sector Weight
1 Healthcare 60.28%
2 Technology 12.21%
3 Industrials 2.92%
4 Consumer Discretionary 0.53%
5 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARGX icon
26
argenx
ARGX
$54.6B
$8.37M 0.94%
87,081
-49,300
-36% -$4.38M
SIOX
27
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$8.17M 0.92%
+1,025,000
New +$14.8M
GWPH
28
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$7.5M 0.85%
+77,000
New +$10.1M
CLLS
29
Cellectis
CLLS
$277M
$7.46M 0.84%
447,970
– –
TVTX icon
30
Travere Therapeutics
TVTX
$5.2B
$7.37M 0.83%
325,678
– –
RVLP
31
DELISTED
RVL Pharmaceuticals plc Ordinary Shares
RVLP
$7.15M 0.81%
+922,200
New +$7.38M
QURE icon
32
uniQure
QURE
$3.03B
$6.71M 0.76%
232,849
+55,000
+31% +$1.53M
AUTL
33
Autolus Therapeutics
AUTL
$407M
$6.67M 0.75%
202,994
-93,257
-31% -$3.07M
GBT
34
DELISTED
Global Blood Therapeutics, Inc.
GBT
$6.03M 0.68%
+147,000
New +$5.51M
ORTX
35
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$5.82M 0.66%
+37,000
New +$5.52M
FSCT
36
DELISTED
ForeScout Technologies, Inc. Common Stock
FSCT
$5.75M 0.65%
59,169
-65,294
-52% -$1.81M
GILT icon
37
Gilat Satellite Networks
GILT
$834M
$5.71M 0.64%
166,663
+3,296
+2% +$30.4K
VKTX icon
38
Viking Therapeutics
VKTX
$3.7B
$5.71M 0.64%
745,727
-114,000
-13% -$1.36M
ARQL
39
DELISTED
Arqule Inc
ARQL
$5.63M 0.63%
2,032,643
+27,400
+1% +$105K
PRQR icon
40
ProQR Therapeutics
PRQR
$243M
$5.37M 0.6%
340,000
-58,749
-15% -$1.08M
NERV icon
41
Minerva Neurosciences
NERV
$185M
$5.27M 0.59%
97,752
-7,547
-7% -$552K
BHVN
42
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$4.92M 0.55%
133,015
-22,500
-14% -$811K
MHK icon
43
Mohawk Industries
MHK
$7.5B
$4.66M 0.53%
+10,661
New +$1.42M
EPZM
44
DELISTED
Epizyme, Inc
EPZM
$4.62M 0.52%
749,502
+350,000
+88% +$2.67M
SYRE icon
45
Spyre Therapeutics
SYRE
$8.54B
$4.49M 0.51%
24,000
-2,124
-8% -$451K
LOGC
46
DELISTED
LogicBio Therapeutics, Inc. Common Stock
LOGC
$4.34M 0.49%
+417,625
New +$5.04M
RCKT icon
47
Rocket Pharmaceuticals
RCKT
$340M
$4.3M 0.48%
+290,001
New +$4.81M
SBBP
48
DELISTED
Strongbridge Biopharma plc.
SBBP
$4.17M 0.47%
931,600
-247,410
-21% -$1.21M
CTMX icon
49
CytomX Therapeutics
CTMX
$675M
$4.13M 0.46%
273,151
+40,000
+17% +$593K
SRRK icon
50
Scholar Rock
SRRK
$5.67B
$4.03M 0.45%
175,511
-121,345
-41% -$2.74M
1
2
3 4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q4 2018 Portfolio in Review

As of Q4 2018, Sphera Funds Management held 136 positions worth $887M, up 1.9% from $871M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Sphera Funds Management deployed $129M of net new capital in Q4 2018, opening 23 new positions and adding to 31 existing holdings. Its largest new stake was Celgene Corp: 465,000 shares worth $29.8M.

By sector, the portfolio is most concentrated in Healthcare at 60% of assets, down from 75% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Merck, an estimated $22.8M trimmed.

  • Sphera Funds Management's largest Q4 2018 buy was Celgene Corp: 465,000 shares worth $29.8M.
  • Sphera Funds Management added most to Viatris in Q4 2018, an estimated $11.4M increase.
  • Sphera Funds Management's biggest Q4 2018 reduction was Merck, cutting an estimated $22.8M.
  • Sphera Funds Management fully exited Johnson & Johnson in Q4 2018, selling an estimated $44.9M.
  • Sphera Funds Management's ten largest holdings make up 51% of its $887M portfolio in Q4 2018.
  • Sphera Funds Management opened 23 new positions and closed 36 in Q4 2018.
  • Sphera Funds Management's portfolio value rose 1.9% quarter-over-quarter to $887M.

Based on Sphera Funds Management's 13F filing for Q4 2018, filed 14 Feb 2019.